{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:34:32Z","timestamp":1759332872363,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323898836"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.mcb.2023.03.005","type":"book-chapter","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T07:46:37Z","timestamp":1689579997000},"page":"23-37","source":"Crossref","is-referenced-by-count":0,"title":["The contribution of automated cytometry in immuno-oncology"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.mcb.2023.03.005_bb0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/07388551.2015.1128876","article-title":"Flow cytometry: Basic principles and applications","volume":"37","author":"Adan","year":"2017","journal-title":"Critical Reviews in Biotechnology"},{"issue":"14","key":"10.1016\/bs.mcb.2023.03.005_bb0015","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0020","first-page":"1","article-title":"Flow cytometry and receptor occupancy in immune-oncology","volume":"22","author":"Audia","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0025","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cll.2017.07.010","article-title":"Applications of mass cytometry in clinical medicine: The promises and perils of clinical CyTOF","volume":"37","author":"Behbehani","year":"2017","journal-title":"Clinics in Laboratory Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2144\/000114543","article-title":"Going with the flow","volume":"62","author":"Blow","year":"2017","journal-title":"BioTechniques"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous cell-non-small cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/cyto.a.23723","article-title":"Optimization of receptor occupancy assays in mass cytometry: Standardization across channels with QSC beads","volume":"95","author":"Bringeland","year":"2019","journal-title":"Cytometry A"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0045","article-title":"The society for immunotherapy of cancer biomarkers task force recommendations review","author":"Butterfield","year":"2017","journal-title":"Seminars in Cancer Biology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0050","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.7150\/thno.18588","article-title":"Circulating tumor cells: Moving biological insights into detection","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0055","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/eji.201970107","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)","volume":"49","author":"Cossarizza","year":"2019","journal-title":"European Journal of Immunology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0060","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1182\/blood-2007-11-120535","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrclinonc.2015.208","article-title":"Revisiting tumor aneuploidy-the place of ploidy assessment in the molecular era","volume":"13","author":"Danielsen","year":"2016","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0070","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3892\/mco.2016.823","article-title":"Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation","volume":"4","author":"Danova","year":"2016","journal-title":"Molecular and Clinical Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1586\/erm.11.33","article-title":"Isolation of rare circulating tumor cells in cancer patients: Technical aspects and clinical implications","volume":"11","author":"Danova","year":"2011","journal-title":"Expert Review of Molecular Diagnostics"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0080","first-page":"1","article-title":"High speed flow cytometry allows the detection of circulating endothelial cells in hemangioblastoma patients","volume":"134\u2013135","author":"De Biasi","year":"2018","journal-title":"Methods"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: Historical perspective of a clinical revolution and emerging preclinical animal models","volume":"8","author":"Decker","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-016-0130-5","article-title":"A current perspective on cancer immune therapy: Step-by-step approach to constructing the magic bullet","volume":"6","author":"D'Errico","year":"2017","journal-title":"Clinical and Translational Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0095","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tibtech.2014.06.007","article-title":"Towards efficient cancer immunotherapy: Advances in developing artificial antigen-presenting cells","volume":"32","author":"Eggermont","year":"2014","journal-title":"Trends in Biotechnology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: The beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0105","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/bs.mcb.2023.03.005_bb0110","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0115","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2016.03.085","article-title":"Systems immune monitoring in cancer therapy","volume":"61","author":"Greenplate","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.21037\/tlcr.2017.05.09","article-title":"Predictive biomarkers of immunotherapy for non-small cell lung cancer: Results from an experts panel meeting of the italian association of thoracic oncology","volume":"6","author":"Gridelli","year":"2017","journal-title":"Translational Lung Cancer Research"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0130","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0140","first-page":"1","article-title":"High-dimensional single-cell cancer biology","volume":"377","author":"Irish","year":"2014","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"10","key":"10.1016\/bs.mcb.2023.03.005_bb0145","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trsl.2017.04.002","article-title":"Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors","volume":"185","author":"Kowalik","year":"2017","journal-title":"Translational Research"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0155","first-page":"1","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.mcb.2023.03.005_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cyto.a.23882","article-title":"Rigor and reproducibility of cytometry practices for immuno-oncology: A multifaceted challenge","volume":"97","author":"Laskowski","year":"2020","journal-title":"Cytometry. Part A"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0165","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.biotechadv.2017.04.001","article-title":"Application of single-cell technology in cancer research","volume":"35","author":"Liang","year":"2017","journal-title":"Biotechnology Advances"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0170","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-017-0479-y","article-title":"Clinical applications of PD-L1 bioassays for cancer immunotherapy","volume":"10","author":"Liu","year":"2017","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JOP.2017.021675","article-title":"Can minimal residual disease determination in acute myeloid leukemia be used in clinical practice?","volume":"13","author":"Luskin","year":"2017","journal-title":"Journal of Oncology Practice\/American Society of Clinical Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0180","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40425-015-0085-x","article-title":"Immune monitoring technology primer: Flow and mass cytometry","volume":"3","author":"Maecker","year":"2015","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0185","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0190","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","article-title":"Biomarkers of response to PD-1\/PD-L1 inhibition","volume":"116","author":"Maleki Vareki","year":"2017","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0195","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00432-012-1190-6","article-title":"Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer","volume":"138","author":"Manzoni","year":"2012","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000320609","article-title":"Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer","volume":"79","author":"Manzoni","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0205","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with Ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: Volume I-pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4939-6788-9_18","article-title":"Fluorochromes for DNA staining and quantitation","volume":"1560","author":"Mazzini","year":"2017","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0220","first-page":"1595","article-title":"Flow cytometric analysis of DNA ploidy in liquid based cytology for cervical pre-cancer and cancer","volume":"18","author":"Mishra","year":"2017","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"issue":"12","key":"10.1016\/bs.mcb.2023.03.005_bb0225","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"14","key":"10.1016\/bs.mcb.2023.03.005_bb0230","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0235","first-page":"36","article-title":"Novel treatment strategies in cancer immunotherapy","volume":"30","author":"Ozverel","year":"2017","journal-title":"Acta Biologica Turcica"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0240","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.3892\/ol.2017.5718","article-title":"Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the portuguese institute of oncology of lisbon","volume":"13","author":"Pinto","year":"2017","journal-title":"Oncology Letters"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0245","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/icb.2015.106","article-title":"Single-cell technologies are revolutionizing the approach to rare cells","volume":"94","author":"Proserpio","year":"2016","journal-title":"Immunology and Cell Biology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0250","doi-asserted-by":"crossref","first-page":"48507","DOI":"10.18632\/oncotarget.17397","article-title":"Implementing liquid biopsies into clinical decision making for cancer immunotherapy","volume":"8","author":"Quandt","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0255","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/bs.mcb.2023.03.005_bb0260","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0265","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0270","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aad6770","article-title":"History of science. Flow cytometry strikes gold","volume":"350","author":"Robinson","year":"2015","journal-title":"Science"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0275","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1286437","article-title":"Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy","volume":"6","author":"Roussel","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0280","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract]","volume":"2013","author":"Schadendorf","year":"2013","journal-title":"European Cancer Congress"},{"issue":"12","key":"10.1016\/bs.mcb.2023.03.005_bb0285","article-title":"Detection of immune checkpoint receptors\u2014A current challenge in clinical flow cytometry","volume":"1","author":"Shibru","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0290","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","article-title":"Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy","volume":"9","author":"\u015aledzi\u0144ska","year":"2015","journal-title":"Molecular Oncology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0295","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.04.019","article-title":"Mass cytometry: Single cells, many features","volume":"165","author":"Spitzer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0300","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00262-013-1416-8","article-title":"An introduction to mass cytometry: Fundamentals and applications","volume":"62","author":"Tanner","year":"2013","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0305","doi-asserted-by":"crossref","DOI":"10.3791\/54615","article-title":"Flow cytometry-based assay for the monitoring of NK cell functions","author":"Tognarelli","year":"2016","journal-title":"Journal of Visualized Experiments"},{"issue":"14","key":"10.1016\/bs.mcb.2023.03.005_bb0310","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0315","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/dna.2017.3981","article-title":"Clinical applications of and challenges in single-cell analysis of circulating tumor cells","volume":"37","author":"Wu","year":"2018","journal-title":"DNA and Cell Biology"},{"key":"10.1016\/bs.mcb.2023.03.005_bb0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0107-3","article-title":"Novel technologies and emerging biomarkers for personalized cancer immunotherapy","volume":"4","author":"Yuan","year":"2016","journal-title":"Journal for Immunotherapy of Cancer"}],"container-title":["Methods in Cell Biology","Flow Cytometry in Immuno-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X23000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X23000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:09:38Z","timestamp":1759248578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X23000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780323898836"],"references-count":63,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2023.03.005","relation":{},"ISSN":["0091-679X"],"issn-type":[{"type":"print","value":"0091-679X"}],"subject":[],"published":{"date-parts":[[2025]]}}}